Cellectis SA has taken a pivotal step in moving forward a potential first allogeneic, or "off-the-shelf," chimeric antigen receptor T-cell (CAR-T) therapy with the initiation of a clinical trial in the US. The company announced the first patient has been dosed in a Phase I clinical study testing the investigational product, UCART123, in patients with acute myeloid leukemia June 27.
Cellectis Moves First Off-The-Shelf CAR-T Into US Clinical Trials
UCART123 is behind the initial wave of CAR-T drugs for cancer but could have a big advantage as an allogeneic, or off-the-shelf, option. A Phase I trial is now under way in patients with acute myeloid leukemia.